Skip to main content

Volume 3 Supplement 1


Linezolid pharmacokinetics in critically ill patients with renal replacement therapy: comparison of equi-dose of continuous veno-venous haemofiltration with continuous veno-venous haemodiafiltration


Linezolid is a commonly used antibiotic for difficult-to-treat Gram-positive infections for which little data is available to guide dosing for different types of renal replacement therapy.


The objective of this study was to compare the population pharmacokinetics of linezolid during continuous venovenous haemofiltration (CVVHF, 30 and continuous venovenous haemodiafiltration (CVVHDF, 15 + 15 We then sought to perform Monte Carlo dosing simulations to determine doses that best achieve pharmacodynamic targets for these patients.


Patients with a clinical indication for linezolid and prescribed either CVVHF or CVVHDF were eligible for participation in this prospective pharmacokinetic study. Patients were administered 600 mg IV 12-hourly. Seven blood samples were collected over one dosing interval and analysed by a validated chromatographic method. Population pharmacokinetic analysis was undertaken using Pmetrics and Monte Carlo simulations evaluated achievement of a pharmacodynamics target of an area under the concentration-time curve from 0-24 hours to minimum inhibitory concentration (AUC0-24/MIC) of 80.


9 CVVHDF and 8 CVVHF were performed in 13 patients. Patient characteristics regimens of CVVHDF and CVVHF were similar. A two compartment linear model best described the data. CVVHDF was associated with a 20.5% higher mean linezolid clearance than CVVHF, without statistical significance (P = 0.39). Both increasing patient weight and decreasing SOFA score were associated with increasing linezolid clearance. The mean (SD) parameter estimates were clearance 3.8 (2.2) L/h, volume of the central compartment 26.5 (10.3) L, intercompartmental clearance constants from central to peripheral (Kcp) 8.1 (12.1) L/h and peripheral to central compartments (Kpc) 3.6 (4.0) L.h-1. Achievement of pharmacodynamics targets was low for a MIC of 2 mg/L with the studied dose.


The present data indicates profound pharmacokinetic variability of linezolid during CVVHF and CVVHDF. Sub-optimal achievement of therapeutic targets occurs at the EUCAST breakpoint MIC of 2 mg/L using 600 mg IV 12-hourly.

Figure 1
figure 1

The median observed linezolid concentration-time p.

Author information

Authors and Affiliations


Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Roger, C., Louart, B., Muller, L. et al. Linezolid pharmacokinetics in critically ill patients with renal replacement therapy: comparison of equi-dose of continuous veno-venous haemofiltration with continuous veno-venous haemodiafiltration. ICMx 3 (Suppl 1), A631 (2015).

Download citation

  • Published:

  • DOI:


  • Renal Replacement Therapy
  • Linezolid
  • Population Pharmacokinetic Analysis
  • Intercompartmental Clearance
  • Monte Carlo Dose